Press Release Date: October 21, 2014
ESNano has announced that it will be moving ahead with plans to conduct Stage one clinical trials on its leading GLP-1/GNP Type 2 diabetes mellitus treatment this year, with the testing to begin in November.
With the use of glucagon like peptides in the treatment of Type 2 diabetes mellitus amounting to a $4 billion dollar a year market and the regimes efficiency as like those of other commonly prescribed treatments being overall quite unremarkable, the industry wide race to bring to the table a more suitable treatment schedule has never been more urgent and ESNano is taking strides to remain at the fore front of the sector.
Testing of ESNano’s GLP-1/GNP binding process was conducted in Pre-Clinical trials which were completed in mid March with positive results achieved across all of the required criteria. The primary aim of the testing being the need to show that the relatively ineffective GLP-1 molecules could experience increased delivery efficiency rates when combined with the barrier crossing capabilities of ESNano’s proprietary golden nano-sphere technology, aims that were demonstrated ably.
With Type 2 Diabetes Mellitus, more commonly known as Adult Onset diabetes affecting approximately 285 million people around the world, some 90% of all diabetes cases according to a 2010 survey by the W.H.O., the need for improved treatment options is compelling on both a human and corporate level and ESNano believes that treatments in combination with its golden nano-sphere technology provide the answer and are moving rapidly to bringing such a regime to market.
Speaking of his company’s decision to enter Stage one clinical trials of their GLP-1/GNP treatment regime, ESNano Technology Development Ltd’s CEO Dr. Hans Zeigler had the following to say” though we are still in the early stages of developing an effective treatment regime for the Type 2 diabetes condition, the results that we have observed in testing of the combined treatment system have shown promising results that we have little choice but to proceed with later stage testing as quickly as is prudent so that we may further amass data on the potential so far demonstrated.”
Go Back to Press Articles